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Lequesne Comparison.
GROUP COMPARISON Mean
difference
Conﬁdence
interval (95%)
p
1 week 0 vs week 1 1,38 -0,15 - 2,90 0,117
1 week 0 vs week 4 2,22 0,25 - 4,18 0,014
1 week 0 vs week 12 3,38 1,14 - 5,63 <0,001
1 week 0 vs week 24 2,80 0,38 - 5,21 0,010
2 week 0 vs week 1 2,92 1,40 - 4,45 <0,001
2 week 0 vs week 4 4,15 2,20 - 6,11 <0,001
2 week 0 vs week 12 2,84 0,60 - 5,08 0,003
2 week 0 vs week 24 2,27 -0,11 - 4,66 0,076
WEEK 0 Group 1 vs Group 2 -0,62 -3,16 - 1,93 0,999
WEEK 1 Group 1 vs Group 2 0,93 -1,62 - 3,48 0,977
WEEK 4 Group 1 vs Group 2 1,32 -1,23 - 3,88 0,824
WEEK 12 Group 1 vs Group 2 -1,16 -3,80 - 1,48 0,927
WEEK 24 Group 1 vs Group 2 -1,14 -3,83 - 1,55 0,942
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VAS Comparison.
GROUP COMPARISON Mean
difference
Conﬁdence
interval (95%)
p
1 week 0 vs week 1 11,98 1,67 - 22,29 0,009
1 week 0 vs week 4 17,03 4,26 - 29,81 0,001
1 week 0 vs week 12 21,17 7,00 - 35,34 <0,001
1 week 0 vs week 24 17,39 2,47 - 32,30 0,009
2 week 0 vs week 1 31,69 21,38 - 42,00 <0,001
2 week 0 vs week 4 32,81 20,10 - 45,52 <0,001
2 week 0 vs week 12 23,30 9,14 - 37,46 <0,001
2 week 0 vs week 24 19,87 5,16 - q 34,57 0,001
WEEK 0 Group 1 vs Group 2 -2,94 -17,82 - 11,94 >0,999
WEEK 1 Group 1 vs Group 2 16,77 1,89 - 31,65 0,014
WEEK 4 Group 1 vs Group 2 12,83 -2,10 - 27,77 0,164
WEEK 12 Group 1 vs Group 2 -0,81 -16,38 - 14,75 >0,999
WEEK 24 Group 1 vs Group 2 -0,46 -16,26 - 15,33 >0,999
Table 2
WOMAC comparison.
GROUP COMPARISON Mean
difference
Conﬁdence
interval (95%)
p
1 week 0 vs week 1 4,38 -2,23 - 11,00 0,52
1 week 0 vs week 4 11,46 2,93 - 19,99 0,001
1 week 0 vs week 12 15,56 5,79 - 25,32 <0,001
1 week 0 vs week 24 13,38 2,94 - 23,82 0,002
2 week 0 vs week 1 20,15 13,54 - 26,77 <0,001
2 week 0 vs week 4 22,79 14,30 - 31,28 <0,001
2 week 0 vs week 12 17,08 7,37 - 26,78 <0,001
2 week 0 vs week 24 15,76 5,39 - 26,14 <0,001
WEEK 0 group 1 vs group 2 -4,33 -15,45 - 6,80 0,966
WEEK 1 group 1 vs group 2 11,44 0,32 - 22,56 0,038
WEEK 4 group 1 vs group 2 7,00 -4,16 - 18,15 0,602
WEEK 12 group 1 vs group 2 -2,81 -14,32 - 8,71 0,999
WEEK 24 group 1 vs group 2 -1,94 -13,60 - 9,71 >0,999ĂNone of the individuals characteristics such as age, genre, BMI or Kell-
green and Lawrence classiﬁcation had any effects on the results. Adverse
effects were: 4,8% of the patients presented effusion and 19,2% of the
patients related discomfort or pain. There was no statistic difference
between the groups.
Conclusion: We concluded that the addition of 1ml of triancinolone to
viscosupplementation brings great improvement to its early results and
does not affect the long-term results, so it should be performed.<br
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MUSCLE STRENGTH AND MUSCLE MASS ONE YEAR AFTER AN INITIAL 16
WEEK INTENSE WEIGHT LOSS: A RANDOMIZED CONTROLLED TRIAL
J. Aaboe 1, H. Bliddal 1, B. Danneskiold-Samsøe 1, P. Christensen 1,
R. Christensen 1,2, M. Henriksen 1. 1 The Parker Inst., Frederiksberg, Denmark;
2 Inst. of Sports Sci. and Clinical Biomechanics, Faculty of Hlth.Sci., Univ. of
Southern Denmark, Odense, Denmark
Purpose: Knee osteoarthritis (OA) and muscle weakness often coexist and
lower muscle strength and less muscle mass pose possible detrimental
effects on physical function and changed muscle metabolism. In obese OA
patients this is particularly important because reductions in muscle
strength and leanmass are known as unsolicited side effects of weight loss.
Thus, participation in exercise regimens followingweight loss is advocated
in the clinic to maintain muscle strength and lean mass. The purpose of
this study was to investigate the effect of a one year exercise treatment
following an intense weight loss compared to dietary counselling or no
attention (control) on leg muscle strength and lean mass.
Methods: A population of obese patients above 50 years of age with knee
OA (ACR criteria) was included in an intense 16 weeks weight loss inter-
vention (NCT NCT00655941). After weight loss, patients were randomized
to one of three groups; a supervised/home based Exercise program,
continuous Dietary support, or a no attention Control group for one year.
The exercise programme consisted of 3 training sessions/week, gradually
translating the intervention from facility based exercises to home based
sessions. At baseline (pre weight loss) and 1 year post weight loss (68
weeks) patients had their body composition analyzed using dual energy X-
ray absorptiometry (DXA) scans together with isometric knee muscle
strength and a self reported symptomatic outcome score (KOOS). The
average of 4 out of the 5 KOOS subscales, excluding sports and recreation
subscale, were used. Changes from baseline to one year follow-up were
compared between groups using analysis of covariance (ANCOVA) with
a factor for group, adjusting for baseline values of the outcome measure.
Results: 171 patients (80% females), 62.7 years of age and BMI 37.3 kg/m2
were included, which at baseline had complete DXA scan and muscle
strength data. The randomization procedure on this “Muscle strength
subsample” resulted in 59, 57 and 55 patients in groups C, D and E,
respectively. After 1 year, 145 patients (85% of baseline) completed the
study (Table 1). Group E did not achieve a statistically signiﬁcant greater
increase in muscle strength compared to Group D and Group C (Table 2).
Similar results were found for lean body mass and KOOS4 (Table 2). While
Group E achieved a lower loss of total body weight (MD: D vs. E; -4.8 kg [CI
Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296 S171-7.5 to -2.0], P¼0.001), total body fat mass (MD: D vs. E; -4.6 kg [CI -7.0 to
-2.2], P¼0.0002), and leg fat mass (MD: D vs. E; -1.7 kg [CI -2.6 to -0.8],
P¼0.0003) compared to Group D, there were no statistically signiﬁcant
differences between Groups E and C in either body composition outcomes
(P>0.15).
Conclusions: This study do not support the hypothesis that exercise
maintenance programmes provides added beneﬁts in muscle strength and
lean mass compared to dietetic counselling or even a no attention control
after 1 year. This study outcome may be due to poor training compliance.
Dietetic counselling resulted in greater total body weight loss and lower
percentage lean mass loss compared to exercise and control. These results
suggest dietetic counselling as a primary maintenance treatment option to
uphold beneﬁcial effects of an initial weight loss on body mass and
composition.
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DICLOFENAC NOT MORE EFFECTIVE THAN ACETAMINOPHEN IN
PATIENTS WITH MILD KNEE OSTEOARTHRITIS: RESULTS OF
A RANDOMIZED CONTROLLED TRIAL IN PRIMARY CARE WITH A 12-
WEEK FOLLOW-UP
S.P. Verkleij, P.A. Luijsterburg, B.W. Koes, A.M. Bohnen,
S.M. Bierma-Zeinstra. Erasmus MC, Rotterdam, Netherlands
Purpose: Guidelines for knee osteoarthritis (OA) recommend acetamino-
phen as the medication of ﬁrst choice when pain medication is needed,
based on safety and suggested effect of acetaminophen in mild stages of
OA. However, in clinical practice, non-steroidal anti-inﬂammatory drugs
(NSAIDs) are still widely used as ﬁrst prescribed medication. This might be
based on the lack of direct comparisons of acetaminophen and NSAIDs in
ﬁrst-time medication users Therefore, we assessed the effectiveness of
Diclofenac versus acetaminophen, regarding improvement in pain, in
patients with mild knee OA who consulted their GP and were willing to
start pain medication.
Methods: This pragmatic open-label RCT, with a 12-weeks follow-up
period, included patients who consulted their GP with a new episode of
knee pain, aged 45 years and older, with a pain severity score of two or
higher on an 11-point numeric rating scale (NRS), and whomet the clinical
American College of Rheumatology (ACR) criteria for knee OA. Patients
were randomly allocated to either Diclofenac (maximum daily dose of 150
mg.) or acetaminophen (maximum daily dose of 3000 mg.) for 2-weeks
and if required an additional 1-2 weeks, which is close to usual care.
During the 12-week follow-up period, patients ﬁlled out a daily diary tomeasure knee pain severity and medication intake. Subsequently, patients
ﬁlled out questionnaires at baseline, 3, 6, 9, and 12-weeks. Primary
outcomes were 4-weeks daily knee pain severity measured with a NRS
collected with a diary, and 3-weekly knee pain severity over the 12-weeks
period measured with an NRS and the Knee Injury and Osteoarthritis
Outcome Score (KOOS) collected from the questionnaires. The secondary
outcome was daily medication intake. Generalized estimated equations
(GEE) analyses were used, according to the intention to treat principle, to
assess differences between the groups and adjusted for age, gender, and
baseline pain differences.
Results: A total of 104 patients were randomized to either Diclofenac
(n¼52) or acetaminophen (n¼52). At baseline, mean knee pain severity
was 5.1 (SD: 1.8) for the acetaminophen and 5.4 (SD: 2.1) for the Diclofenac
group. At day 1 from the diary, mean knee pain severity was 4.3 (SD: 1.8)
for acetaminophen and 4.9 (SD: 1.9) for Diclofenac. Although there seems
to be a slightly stronger reduction in knee painwithin the ﬁrst 2-weeks for
Diclofenac users, differences in knee pain over the ﬁrst 4-weeks between
the groups were not statistically signiﬁcant (b: 0.1; 95% CI: -0.7 to 0.9).
Over 12-weeks, no statistically differences were found between the groups
knee pain severity measured with KOOS (b: -3.1; 95% CI: -9.7 to 3.5) and
the NRS (b: -0.24; 95% CI: -1.1 to 0.6). Also, we found no signiﬁcant
differences between the groups regarding total medication intake (OR: 1.4;
0.6 to 3.0). After 4-weeks in the Diclofenac group, 18 patients still used
Diclofenac, 6 patients used acetaminophen, one ibuprofen, and 21 patients
stopped taking medication. After 4-weeks in the acetaminophen group, 16
patients still used acetaminophen, 1 patient used both acetaminophen and
Celebrex, and 24 stopped their medication.
Conclusions:We found no difference in effectiveness between Diclofenac
vs. acetaminophen in reducing pain in patients with mild knee OA. These
results endorse the recommendation of acetaminophen as 'ﬁrst choice
medication' in (inter)national guidelines regarding primary care patients
with knee OA.
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